The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats

Growth Hormone and IGF Research

Volumn 11, Issue 5, 2001, Pages 266-272

  Andersen, N B ^a   Malmlof K ^b   Johansen, P B ^b   Andreassen, T T ^a   Ortoft, G ^a   Oxlund, H ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Bone bending strength; Bone formation; Glucocorticoid; Growth hormone secretagogue; Muscle strength; Muscle tetanic tension

Indexed keywords

CALCEIN; GLUCOCORTICOID; GROWTH HORMONE SECRETAGOGUE; IPAMORELIN; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PENTOBARBITAL; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE STRENGTH; CATABOLISM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTROCNEMIUS MUSCLE; IN VIVO STUDY; MUSCLE STRENGTH; MUSCLE TETANIC CONTRACTION; MUSCLE WEAKNESS; NONHUMAN; OSSIFICATION; PERIOSTEUM; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE;

EID: 0035726718     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.2001.0239     Document Type: Article

References (43)

1. Steroid myopathy in connective tissue disease
2. Evidence that prednisone-induced myopathy is reversed by physical training
3. Turnover of skeletal muscle contractile proteins in glucocorticoid myopathy
4. Steroid-induced fractures and bone loss in patients with asthma
5. Glucocorticoid-induced osteoporosis
6. The effect of glucocorticoid and growth hormone on the skeletal system in young growing rats
7. Growth hormone and mild exercise in combination increases markedly muscle mass and tetanic tension in old rats
8. Glucocorticoid action on protein synthesis and protein breakdown in isolated skeletal muscles
9. Glucocorticoid-induced atrophy is not due to impared excitability of rat muscle
10. Diaphragm atrophy and weakness in cortisone-treated rats
11. Growth hormone administration can improve growth in glucocorticoid-injected rats without affecting the lymphocytopenic effect of the glucocorticoid
12. Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia
13. Effects of growth hormone on skeletal muscle. I. Studies on normal adult rats
14. Skeletal muscle fibre types and myosin ATPase activity do not change with age or growth hormone administration
15. Growth hormone stimulates bone formation and strength of cortical bone in aged rats
16. The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats
17. Growth hormone and mild exercise in combination markedly enhance cortical bone formation and strength in old rats
18. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats
19. Growth hormone secretagogue increases muscle strength during remobilization after canine hindlimb immobilization
20. Growth hormone prevents steroid-induced growth depression in health and uremia
21. L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppresion of GH secretion
22. Effect of GHRP-6 and GHRH on GH secretion in rats following chronic glucocorticoid treatment
23. Ipamorelin, the first selective growth hormone secretagogue
24. Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats
25. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
26. Glucocorticoid treatment or food deprivation counteract the stimulating effect of growth hormone on rat cortical bone strength
27. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum
28. Kidney tissue insulin-like growth factor I and initial renal growth in diabetic rats: Relation to severity of diabetes
29. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals
30. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index
31. Effects of human growth hormone in men over 60 years old
32. Effects of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men
33. Effect of growth hormone and resistance exercise on muscle growth and strength in older men
34. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein syntesis in healthy subjects over 60 years old
35. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH scretagogue (MK-677) in healthy elderly subjects
36. Dexamethasone inhibits growth hormone induction of insulin like growth factor-I (IGF-I) messenger ribonucleic acid (mRNA) in hypophysectomized rats reduces IGF-I mRNA abundance in the intacts rat
37. Serum free insulin-like growth factor-I is dose-dependently decreased by methylprednisolone and related to body weight changes in rats
38. Free insulin-like growth factors (IGF-I and IGF-II) in human serum
39. Two-month treatment of obese subjects with oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
40. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
41. Growth hormone status during long-term hexarelin therapy
42. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption